Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sundrug CoSDGCF 79 Earnings Yield (Joel Greenblatt) % is 10.62% as of Mar. 2026, which is 12% above its 10-year median of 9.52. GuruFocus rates SDGCF with a GF Score™ of 79/100 and a GF Value™ of $35.45. The stock has 1 warning sign investors should review. Among 682 Healthcare Providers & Services companies, Sundrug Co ranks better than 85.48% on this metric.
Sundrug Co's Enterprise Value for the quarter that ended in Mar. 2026 was $3,156 Mil.
Sundrug Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $305 Mil. Sundrug Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 10.62%.
The historical rank and industry rank for Sundrug Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
SDGCF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.13 Med: 9.52 Max: 15.11
Current: 11.01
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Sundrug Co was 15.11%. The lowest was 6.13%. And the median was 9.52%.
SDGCF's Earnings Yield (Joel Greenblatt) % is ranked better than 85.48% of 682
companies
in the Healthcare Providers & Services industry
Industry Median: 3.425
vs SDGCF: 11.01
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sundrug Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 10.47%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Sundrug Co (OTCPK:SDGCF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Sundrug Co Earnings Yield (Joel Greenblatt) % Related Terms
Sundrug Co Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sundrug Co's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sundrug Co Earnings Yield (Joel Greenblatt) % Chart
Sundrug Co Earnings Yield (Joel Greenblatt) % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Sundrug Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sundrug Co Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sundrug Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sundrug Co's Earnings Yield (Joel Greenblatt) % falls into.
Sundrug Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Sundrug Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
Sundrug Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $305 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 10.62% mean?
Sundrug Co (SDGCF) has a Earnings Yield (Joel Greenblatt) % of 10.62% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Sundrug Co and its competitors. This is 12% above median its historical median of 9.52. Over the past decade, Sundrug Co's Earnings Yield (Joel Greenblatt) % has ranged from 6.13 to 15.11. According to the industry distribution chart, Sundrug Co ranks #99 out of 682 companies in the Healthcare Providers & Services industry, placing it in the top 14.5%.
Is Sundrug Co's Earnings Yield (Joel Greenblatt) % too high?
Sundrug Co's current Earnings Yield (Joel Greenblatt) % of 10.62% is 12% above median its 10-year median of 9.52. Over the past 10 years, this metric has ranged from a low of 6.13 to a high of 15.11. The Healthcare Providers & Services industry median Earnings Yield (Joel Greenblatt) % is 3.43. Sundrug Co's value of 10.62% is 210.1% above this industry median. Based on the distribution chart, Sundrug Co ranks #99 out of 682 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Sundrug Co has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Sundrug Co's Earnings Yield (Joel Greenblatt) % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sundrug Co ranks #99 out of 682 companies for Earnings Yield (Joel Greenblatt) %. This places Sundrug Co in the top 15% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.43. Sundrug Co's value of 10.62% is 210.1% above this benchmark. Historically, Sundrug Co's own Earnings Yield (Joel Greenblatt) % has ranged from 6.13 to 15.11 over the past decade. While the company's 10-year median is 9.52 vs. the industry median of 3.43, Sundrug Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.43, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sundrug Co's current Earnings Yield (Joel Greenblatt) % of 10.62% is 210.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Sundrug Co and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sundrug Co's current Earnings Yield (Joel Greenblatt) % is 10.62%, which is 12% above median its own 10-year median of 9.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sundrug Co stock overvalued right now?
Sundrug Co (SDGCF) has a current Earnings Yield (Joel Greenblatt) % of 10.62%. The stock's GF Value™ is $35.45, compared to a current price of $28.18 — trading 20.5% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 10.62%, which is 12% above median its 10-year median of 9.52 and 210.1% above the Healthcare Providers & Services industry median of 3.43. Sundrug Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Sundrug Co (SDGCF), the current Earnings Yield (Joel Greenblatt) % is 10.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sundrug Co (SDGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Sundrug Co stock appears to be undervalued.
The current stock price of $28.18 is trading 20.5% below its estimated GF Value™ of $35.45.
Key valuation signals for SDGCF:
Earnings Yield (Joel Greenblatt) %: 10.62% (12% above median its 10-year median of 9.52)
GF Value™: $35.45 vs. price of $28.18 (20.5% below fair value)
Industry Position: 210.1% above the Healthcare Providers & Services median (#99 of 682)
No single metric tells the full story. See the SDGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sundrug Co Ltd is a Japanese-based company engaged in the operation of drug stores and discount stores. The Group operates through two segments: the Drug Store Business, which mainly sells pharmaceuticals, cosmetics, and daily necessities, and the Discount Store Business, which mainly sells food products, household goods, and other related items. It generates the majority of its revenue from the Drugstore business segment.
79GF Score
Get the complete analysis for SDGCF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDGCF has been successfully added to your 
